AbbVie

1639 articles about AbbVie

• 

  AbbVie Terminates Caribou CAR-T Contract in Culling of Cancer Pipeline

  9/27/2023

  Soon after cancelling its contract with I-Mab, AbbVie has now also turned its back on a partnership with Berkeley-based Caribou Biosciences that was focused on advancing allogeneic CAR-T therapeutics.

• AbbVie Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

  9/25/2023

  AbbVie announced that the European Commission has granted conditional marketing authorization for TEPKINLY® as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

• 

  AbbVie Ends I-Mab Deal for CD47 Antibody Compounds, Products

  9/25/2023

  After dropping an early-stage study more than a year ago, AbbVie has finally terminated its CD47 collaboration with I-Mab, leaving up to $1.3 billion in potential milestone payments on the table.
• 

  Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

  9/15/2023

  In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.
• 

  AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program

  9/14/2023

  The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

• AbbVie Calls on Public to Vote for the 2023 AbbVie Cystic Fibrosis Scholarship "Thriving Students"

  9/13/2023

  AbbVie today announced the start of its two-week public voting period for the 2023 Thriving Undergraduate and Graduate Scholarships.

• 

  The Top 12 Biopharma Companies Hiring Now

  9/13/2023

  Job posting activity continued to decline in August, but job seekers came out of the woodwork, with both job views and applicants increased from July.

• Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

  9/13/2023

  Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA.

• 

  AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

  9/13/2023

  Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.

• AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease

  9/12/2023

  AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI®, 600 mg intravenous [IV] induction at week 0, 4 and 8 and 360 mg subcutaneous injection [SC] starting at week 12 and every 8 weeks thereafter) versus ustekinumab (STELARA®, IV dose at week 0 and 90 mg SC every 8 weeks thereafter) through week 48 in patients with moderately to severely active Crohn's disease who have failed one or more anti-TNFs.

• AbbVie Declares Quarterly Dividend - September 08, 2023

  9/8/2023

  The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.48 per share.

• 

  AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

  9/8/2023

  As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.

• AbbVie to Present at the Morgan Stanley Healthcare Conference - September 6, 2023

  9/6/2023

  AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023.

• AbbVie Awards 45 Scholarships to U.S. Students Living With Chronic, Immune-Mediated Diseases

  8/30/2023

  AbbVie today announced the 2023-2024 class of AbbVie Immunology Scholarship recipients.

• AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis

  8/28/2023

  AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for risankizumab (SKYRIZI®, 1200 mg intravenous [IV] [induction dose] and 180 mg and 360 mg subcutaneous [SC] [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis.

• 

  AbbVie Removes Two Early-Stage Cancer Assets from Pipeline

  8/24/2023

  The company appears to be terminating the development of two Phase I antibody-drug conjugates in cancer, ABBV-011 and the Pfizer-partnered ABBV-647.

• AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults

  8/17/2023

  AbbVie announced that the European Commission has approved AQUIPTA® for the prophylaxis of migraine in adults who have four or more migraine days per month.

• AbbVie Reports Second-Quarter 2023 Financial Results

  7/27/2023

  AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2023.

• SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study

  7/26/2023

  AbbVie (NYSE: ABBV) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI® (risankizumab) compared to Otezla® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy.1

• AbbVie and Calibr Expand Strategic Collaboration to Advance Several Preclinical and Early-stage Clinical Assets

  7/26/2023

  AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest.